-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
November 2018
-
2018 ASTRO Guideline for Palliative Thoracic Radiation Therapy for NSCLC: The Balance Between Curative and Palliative Radiotherapy
By Shalini K. Vinod, MBBS, MD Posted: October 2018 The standard of care for patients with inoperable stage III NSCLC is curative radiotherapy and concurrent chemotherapy.1 However, there are numerous factors that may preclude this approach, including poor respiratory function and large tumor volume—both of which are surrogates for unacceptable radiation doses to normal lung…
-
The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management
By Andrew R. Haas, MD, PhD Posted: October 2018 Lung cancer remains the leading global cause of cancer-related mortality.1 Due to the lack of symptoms at the time early-stage disease first manifests, the majority of patients still present with advanced-stage disease. Optimal treatment and patient outcome is incumbent on thorough radiographic and invasive staging. In…
-
Living in the “Gray Zone”: Entering a New Age in Radiation Therapy for Patients with Lung Cancer
Posted: October 2018 Patients with stage III or more advanced lung cancer tend to be older and less healthy than patients with other stage III cancers. Because of this, selection of optimal therapies for individual patients, including stereotactic body radiation therapy (SBRT), is more nuanced. With the advent of improvements in technology, more multidisciplinary approaches…
-
Top Science in Lung Cancer Featured at WCLC 2018
By Kara Nyberg, PhD Posted: October 2018 The Presidential Symposium at the IASLC World Conference on Lung Cancer 2018 (WCLC) showcased the top five scientific abstracts highlighting progress in detecting and treating different forms of lung cancer and mesothelioma. These presentations featured four positive clinical trials that advance current treatment standards and one negative clinical…
-
A Review of CancerSEEK
By Pierre P. Massion, MD Posted: October 2018 Early detection is key to disease management. For example, there are numerous data in hypertension, diabetes, coronary artery disease, and renal dysfunction showing strong correlation between early diagnosis and improved outcome.1 Noninvasive means of early detection of cancer is around the corner.2-4 Recent research has positioned the…
-
The IASLC Provides More Than Just Scientific Knowledge at Tangier Conference
By Anna Wrona, MD, PhD Posted: October 2018 The IASLC Africa Conference on Lung Cancer 2018 in Tangier, Morocco, held last spring, provided participants with unique expert perspectives in lung cancer epidemiology, diagnostics, and treatment. This meeting created a collegial environment for open discussion among its international participants. The program offered a number of substantive…
-
The Treatment of Patients with Oligometastatic Lung Cancer
By Anne-Marie C. Dingemans, MD, PhD, and Lizza E.L. Hendriks, MD, PhD Posted: October 2018 Patients with stage IV NSCLC are generally viewed as having incurable disease; however, for years, patients presenting with a solitary brain or adrenal metastasis have been treated with local ablative treatment (LAT) with curative intent, and multiple series have shown…
-
CAR-T Cells for Lung Cancer: Q&A with Dr. Charu Aggarwal
Posted: October 2018 With complete remissions seen in up to 90% of patients with B-cell acute lymphoblastic leukemia (ALL), a breakthrough therapy designation in multiple myeloma, and a first-of-its-kind approval for children and young adults with ALL, CAR-T cells have transformed the treatment landscape for hematologic malignancies. Progress in solid tumors, however, has been considerably…
-
The IASLC Fight Against Lung Cancer in Peru and Latin America
By Dr. Luis E. Raez, MD Posted: October 2018 Peru is one of the largest Latin American countries, with a population of approximately 28 million people. Cancer is not yet a leading cause of mortality because of the young median age of the population and other factors like the high prevalence of infectious diseases; in…
-
Antoinette Wozniak, MD
Posted: October 2018 Antoinette Wozniak, MD, moved to Hillman Cancer Center at University of Pittsburgh Medical Center in September 2018, where she is now a professor of medicine, leader of the Lung Cancer Disease Team, and associate director of clinical research. She was previously with the Karmanos Cancer Institute for more than 25 years.
View ILCN Archives
Provider Resources
Popular Articles